The long‐term effects of direct‐acting antiviral therapies (DAAs) for chronic hepatitis C
(CHC) remain uncertain. The objective of this systematic review and meta‐analysis was to …

Background Liver cancer is the sixth most commonly diagnosed cancer and the fourth most
common cause of cancer death. The purpose of this work is to find new diagnostic …

Simple Summary Hepatocellular carcinoma (HCC) recurrence is the major obstacle
concerning patients' survival. Tertiary prevention by antiviral therapies could reduce HCC …

Background Hepatocellular carcinoma (HCC) is one of the most common clinical
malignancies quite susceptible to recurrence and metastasis. Despite several improvements …

Unconventional prefoldin RNA polymerase II subunit 5 interactor (URI1) has emerged as an
oncogenic driver in hepatocellular carcinoma (HCC). Although the hepatitis B virus (HBV) …

Introduction Hepatocellular carcinoma (HCC) accounts for more than 90% of liver cancers
and is ranked as the fifth most common malignancy. Androgen receptor (AR) may promote …

This study set out to observe the value of miR-885-5p in the prognosis evaluation of liver
cancer patients after transcatheter arterial chemoembolization. Sixty liver cancer patients …

Purpose This study was conducted to investigate the differentially expressed profiles of long
non-coding RNAs (lncRNAs) in HBV-associated HCC (HBV-HCC), which may serve as …

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related mortality
worldwide. The Brazilian Society of Hepatology (SBH) published in 2020 the updated …

Aberrantly low expression of NF‑κB inhibitor α (IκBα) is observed in hepatocellular
carcinoma (HCC), yet the underlying mechanism via which IκBα regulates HCC remains …